Advanced Filters
noise

oral-cavity-cancer Clinical Trials

A listing of oral-cavity-cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 91 clinical trials
K Keshav Murthy, MS

Newer Therapeutic Targets in Head and Neck Cancers

Based on the recently identified mutations in HNSCCs, the major pathologic pathways implicated in the tumorigenesis of HNSCC include dysregulation of four processes: cellular survival and proliferation (e.g., TP53, EGFR, MET, and PIK3CA); cell-cycle control (e.g., CDKN2A and CCND1); cellular differentiation (e.g., NOTCH1); and Adhesion and invasion signaling (e.g., FAT1).7 …

18 - 100 years of age All Phase N/A
I Ijeoma Eleazu, Pharm.D

Microbiome in Head and Neck Squamous Cell Carcinoma

This study aims to determine whether dysbiosis actively contributes to HNSCC and if so, the underlying molecular mechanisms.

18 - 100 years of age All Phase N/A

Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology

The purpose of this study is to get images (pictures) of oral lesions, which occur inside the mouth, before the patient's surgery using a special camera. These pictures will be used in our research to evaluate a new technology that uses a laser and takes pictures of the microscopic structure …

18 years of age All Phase N/A

Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment

The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.

15 - 90 years of age All Phase N/A

SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography

This clinical trial aims to assess the efficacy of Optical Coherence Tomography (OCT) in the early diagnosis of oral cancer. It focuses on Oral Potentially Malignant Disorders (OPMDs) as precursors to Oral Squamous Cell Carcinoma (OSCC). Despite the availability of oral screening, diagnostic delays persist, underscoring the importance of exploring …

18 - 99 years of age All Phase N/A
M Manuel Weber, MD, DMD

Prediction of Malignant Transformation of Oral Leukoplakia Using a MAGE-A-based Immunoscore

Oral squamous cell carcinomas (OSCC) is among the most common malignancies worldwide. Early detection and prevention of OSCC is thought to have the highest potential to reduce morbidity and mortality. In prevention, the main focus is on precancerous lesions, especially oral leukoplakia (OLP), as up to 67% of OSCC arise …

18 - 80 years of age All Phase N/A
L Lai-ping Zhong, MD, PhD

PDO Based Drug Sensitive Test in R/M SGC

To evaluate the consistency of drug efficacy between the clinical systemic treatment and drug sensitive test based on patient-derived organoid in R/M SGC patients, using a prospective and multicenter observational study to increase the generalizability and reliability of research conclusion.

18 - 80 years of age All Phase N/A
S Saif M Aljabab, DABR, MBA

Arabic PRO Measures for Head and Neck Cancer Radiotherapy.

The goal of Arabic patient-reported outcome measures during radiotherapy for head and neck cancer is to test the patient-reported outcome measure (PROM) tools. PROM tools are not validated cross-culturally in Arabic-speaking patient populations, which limits their use in our clinical setting. Validation of these PROM tools will allow clinicians to …

18 years of age All Phase N/A
E Eyiwunmi Laseinde

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of …

18 years of age All Phase N/A
S Sarah Ginn

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, …

18 years of age All Phase N/A

Simplify language using AI